118 related articles for article (PubMed ID: 2635635)
1. [Prognostic value of prostatic acid phosphatase in stage B and C prostatic cancer. Apropos of 84 cases].
Guerin JL; Canal P; Douchez J; Soula G
Bull Cancer; 1989; 76(10):1077-82. PubMed ID: 2635635
[TBL] [Abstract][Full Text] [Related]
2. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
Moul JW; Connelly RR; Perahia B; McLeod DG
J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
[TBL] [Abstract][Full Text] [Related]
3. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
Hamami G
Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer].
Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J
Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis of prostate cancer with elevated prostatic acid phosphatase].
Saito T; Kitamura Y; Komatsubara S
Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of advanced prostatic carcinoma.
Lukkarinen O; Lehikoinen K
Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
8. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
Morote Robles J; Lorente JA; Reig C; López Pacios MA; de Torres JA; Soler Roselló A
Actas Urol Esp; 1994 May; 18(5):559-61. PubMed ID: 7521563
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
[TBL] [Abstract][Full Text] [Related]
10. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
11. [Prostatic acid phosphatase and prostatic specific antigen measured by immunoenzyme assay].
Fuse H; Akimoto S; Shimazaki J
Hinyokika Kiyo; 1986 Dec; 32(12):1813-9. PubMed ID: 2435130
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
13. [Role of prostatic acid phosphatases in the treatment of adenocarcinoma of the prostate].
Perrin P; Clairet F; Fleury-Goyon MC; Durand L
J Urol (Paris); 1984; 90(1):19-22. PubMed ID: 6202800
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 169 patients with prostate cancer].
Okaneya T; Mizusawa H; Yoneyama T; Taguchi I; Komiyama I; Kawakami M; Hosaka K; Tsuruta T; Murata Y; Komatsu H; Misawa K; Kiyokawa H
Hinyokika Kiyo; 1996 Aug; 42(8):563-7. PubMed ID: 8889563
[TBL] [Abstract][Full Text] [Related]
15. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
16. Prostatic acid phosphatase: current concepts.
Romas NA
Semin Urol; 1983 Aug; 1(3):177-85. PubMed ID: 6379804
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
Sakai H; Shiraishi K; Minami Y; Yushita Y; Kanetake H; Saito Y
Prostate; 1991; 19(3):265-72. PubMed ID: 1946042
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of a monoclonal antibody-based enzyme immunoassay (IQ(Bio) PAP-AELIA kit) for prostatic acid phosphatase].
Koshida K; Naito K; Hisazumi H
Hinyokika Kiyo; 1987 Oct; 33(10):1703-7. PubMed ID: 3328502
[TBL] [Abstract][Full Text] [Related]
19. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
20. Radical external beam radiation therapy for prostate carcinoma.
Garrett PG; Herman JG; Rawlings GA; Hawkins NV; Gospodarowicz MK; Keen CW; Rider WD
J Can Assoc Radiol; 1984 Jun; 35(2):139-43. PubMed ID: 6480665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
